GlassScriptPhysician profile
Vittorio Mena
NPI 1942698717
$53,098.88
in general payments reported to CMS, 2019-2025
17 companies · $5,930 in 2025
The $5,930 reported for 2025 was more than what 96% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
See the full distribution for Corneal and Contact Management
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,042 · 2020: $5,591 · 2021: $7,456 · 2022: $19K · 2023: $6,148 · 2024: $4,520 · 2025: $5,930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,115 · Food and Beverage: $4,373 · Travel and Lodging: $2,610 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Honoraria: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,115.00 |
| Food and Beverage | $4,372.55 |
| Travel and Lodging | $2,610.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Honoraria | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $32,823.49 | 2020-2025 | Total30, Dailies Total1, Precision 1 |
| Visioneering Technologies, INC. | $7,280.67 | 2019-2023 | |
| Coopervision INC. | $5,130.77 | 2020-2025 | Misight Contact Lens, Myday Contact Lens |
| Bausch & Lomb Americas INC. | $4,599.99 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Allergan, INC. | $725.08 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $542.69 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $486.88 | 2023-2024 | Ce-Marked Kxla System |
| Dompe US, INC. | $420.86 | 2023-2025 | Oxervate |
| Abbvie INC. | $243.46 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $154.60 | 2019-2021 | |
| Harrow Eye, LLC | $148.70 | 2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $124.09 | 2019 | |
| Eyevance Pharmaceuticals LLC | $122.00 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $121.90 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $111.48 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $32.81 | 2019 | |
| Optos, INC. | $29.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vittorio Mena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.